John F. Valentine
Rating: 4.9 of 5
( out of 45 reviews )

John F. Valentine, MD

Languages spoken: English

Clinical Locations

Primary Location

South Jordan Health Center

5126 West Daybreak Parkway
South Jordan , UT 84009
801-213-4500
Get Directions

University of Utah Hospital

Gastroenterology Endoscopy Center
50 N Medical Dr
Salt Lake City , UT 84132
801-213-9797
Get Directions

Gastroenterology /GI Clinic UUH

Gastroenterology, Area E
50 N Medical Dr
Salt Lake City , UT 84132
801-213-9797
Get Directions

  • John F. Valentine, MD, is a Professor of Medicine at the University of Utah School of Medicine in the Division of Gastroenterology, Hepatology and Nutrition and specializes in ulcerative colitis and Crohn's disease. His clinical interests and expertise are in inflammatory diseases of the intestinal tract that include inflammatory bowel disease (ulcerative colitis and Crohn's disease) and celiac disease.

    Dr. Valentine received his M.D. degree from the University of Texas Medical School at Houston in 1985. He received his training in Internal Medicine at the Medical College of Virginia-Virginia Commonwealth University Medical Center and his training in Gastroenterology at the University of Florida. While on faculty at the University of Florida, he rose to the position of Professor of Medicine, served as the Chief of the Gastroenterology Section at the Malcom Randal Veterans Administration Medical Center, and founded the Southeastern Center for Inflammatory Bowel Disease. He remains active with the Crohn's and Colitis Foundation of America and has served a Co-Chair of the CCFA patient education committee and was a member of the editorial board for the journal Inflammatory Bowel Disease. Dr. Valentine is a Fellow in the American Gastroenterological Association and the director of the University of Utah Inflammatory Bowel Disease Center. Dr. Valentine has extensive experience with treating patients with inflammatory bowel disease and he is developing laboratory research and clinical trials in ulcerative colitis and Crohn's disease in order to expand the understanding and treatment options for patients with these diseases.

    Specialties

    Board Certification

    American Board of Internal Medicine

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 45 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    I was heard about my concerns and provided a remedy that was explained clearly

    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    Best doctor I have ever had treating me and my Crohn's

    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    He is very professional he explains everything to you that you need to hear

    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    Dr Valentine if one of the best doctors I've ever had!

    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    He is the most amazingly excellent physician and I have had many very good ones

    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Knowledgeable, thorough, compassionate

    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Dr Valentine has always been very positive to me. He treats me with respect and shares his Knowledge well!

    UH HOSPITALS AND CLINICS
    Rating: 4 out of 5

    If there is a little bit more explanation about my situation will be perfect.

    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    Dr. Valentine had someone he was mentoring talk to me. She asked good questions and was specific abt my situation. Dr. Valentine was in the background but actively participating, coaching her as needed. I had a question abt an over the counter medicine that I had started taking which was related to my condition and asked his advice abt it's efficacy. Dr. Valentine gave his opinion which was very helpful!

  • John F. Valentine, MD, is a Professor of Medicine at the University of Utah School of Medicine in the Division of Gastroenterology, Hepatology and Nutrition and specializes in ulcerative colitis and Crohn's disease. His clinical interests and expertise are in inflammatory diseases of the intestinal tract that include inflammatory bowel disease (ulcerative colitis and Crohn's disease) and celiac disease.

    Dr. Valentine received his M.D. degree from the University of Texas Medical School at Houston in 1985. He received his training in Internal Medicine at the Medical College of Virginia-Virginia Commonwealth University Medical Center and his training in Gastroenterology at the University of Florida. While on faculty at the University of Florida, he rose to the position of Professor of Medicine, served as the Chief of the Gastroenterology Section at the Malcom Randal Veterans Administration Medical Center, and founded the Southeastern Center for Inflammatory Bowel Disease. He remains active with the Crohn's and Colitis Foundation of America and has served a Co-Chair of the CCFA patient education committee and was a member of the editorial board for the journal Inflammatory Bowel Disease. Dr. Valentine is a Fellow in the American Gastroenterological Association and the director of the University of Utah Inflammatory Bowel Disease Center. Dr. Valentine has extensive experience with treating patients with inflammatory bowel disease and he is developing laboratory research and clinical trials in ulcerative colitis and Crohn's disease in order to expand the understanding and treatment options for patients with these diseases.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Gastroenterology
    Board Certification
    American Board of Internal Medicine

    Education history

    Undergraduate Microbiology - University of Texas at Arlington B.S.
    Professional Medical Medicine - University of Texas Medical School at Houston M.D.
    Internship/Residency Internal Medicine - Medical College of Virginia Intern/Resident
    Fellowship Gastroenterology - University of Florida College of Medicine Fellow

    Selected Publications

    Journal Article

    1. Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, Gold MS, Valentine JF, Smoot DT, Harris ML, Oliva-Hemker M, Bayless TM, Burek CL, Brant S (2010). NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. The American journal of gastroenterology, 105(2), 378-86. (Read full publication)
    2. Faubion WA Jr, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir M (2013). EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. The American journal of gastroenterology, 108(12), 1891-900. (Read full publication)
    3. Somineni HK, Nagpal S, Venkateswaran S, Cutler DJ, Okou DT, Haritunians T, Simpson CL, Begum F, Datta LW, Quiros AJ, Seminerio J, Mengesha E, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Iskandar H, Dryden GW, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kuemmerle JF, Lazarev M, Li E, Mannon P, Moulton DE, Newberry RD, Patel AS, Pekow J, Saeed SA, Valentine JF, Wang MH, McCauley JL, Abreu MT, Jester T, Molle-Rios Z, Palle S, Scherl EJ, Kwon J, Rioux JD, Duerr RH, Silverberg MS, Zwick ME, Stevens C, Daly MJ, Cho JH, Gibson G, McGovern DPB, Brant SR, Kugathasan (2021). Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease. American journal of human genetics, 108(3), 431-445. (Read full publication)
    4. Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S, Chopra P, Alexander JS, Baldassano RN, Cross RK, Dassopoulos T, Dhere TA, Duerr RH, Hanson JS, Hou JK, Hussain SZ, Isaacs KL, Kachelries KE, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kumar A, Kwon JH, Lazarev M, Mannon P, Moulton DE, Osuntokun BO, Patel A, Rioux JD, Rotter JI, Saeed S, Scherl EJ, Silverberg MS, Silverman A, Targan SR, Valentine JF, Wang MH, Simpson CL, Bridges SL, Kimberly RP, Rich SS, Cho JH, Rienzo AD, Kao LWH, McGovern DPB, Brant SR, Kugathasan (2015). Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology, 149(6), 1575-1586. (Read full publication)
    5. Brant SR, Okou DT, Simpson CL, Cutler DJ, Haritunians T, Bradfield JP, Chopra P, Prince J, Begum F, Kumar A, Huang C, Venkateswaran S, Datta LW, Wei Z, Thomas K, Herrinton LJ, Klapproth JA, Quiros AJ, Seminerio J, Liu Z, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Dryden GW, Hanson JS, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kwon JH, Lazarev M, Li E, Mack D, Mannon P, Moulton DE, Newberry RD, Osuntokun BO, Patel AS, Saeed SA, Targan SR, Valentine JF, Wang MH, Zonca M, Rioux JD, Duerr RH, Silverberg MS, Cho JH, Hakonarson H, Zwick ME, McGovern DP, Kugathasan (2017). Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology, 152(1), 206-217.e2. (Read full publication)
    6. Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD, Clinical Research Alliance of the Crohn's and Colitis Foundation (2018). Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 155(4), 1098-1108.e9. (Read full publication)
    7. Lewis JD, Sandler R, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson J, Suskind D, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen B, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H, DINE-CD Study Group (2021). A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults with Crohn's Disease. Gastroenterology, 161, 837-852.e9. (Read full publication)
    8. Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries T (2009). Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut, 58(10), 1354-62. (Read full publication)
    9. Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ (2014). Increased IFN-¿-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-¿ production. Journal of immunology (Baltimore, Md., 193(3), 1024-34.
    10. Davis MK, Valentine JF, Weinstein DA, Polyak (2010). Antibodies to CBir1 are associated with glycogen storage disease type Ib. Journal of pediatric gastroenterology and nutrition, 51(1), 14-8. (Read full publication)
    11. Naser SA, Ghobrial G, Romero C, Valentine J (2004). Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet (London, England), 364(9439), 1039-44. (Read full publication)
    12. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert M (2005). Sargramostim for active Crohn's disease. The New England journal of medicine, 352(21), 2193-201. (Read full publication)
    13. Ost KS, O'Meara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, Bell R, Catanzaro JR, Song D, Singh S, Call DH, Hwang-Wong E, Hanson KE, Valentine JF, Christensen KA, O'Connell RM, Cormack B, Ibrahim AS, Palm NW, Noble SM, Round J (2021). Adaptive immunity induces mutualism between commensal eukaryotes. Nature, 596(7870), 114-118. (Read full publication)
    14. Ahmadi A, Li Q, Muller K, Collins D, Valentine JF, Drane W, Polyak (2010). Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflammatory bowel diseases, 16(6), 974-81. (Read full publication)
    15. Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff (2015). Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflammatory bowel diseases, 21(8), 1809-16. (Read full publication)
    16. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri (2015). Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory bowel diseases, 21(6), 1329-40. (Read full publication)
    17. Koboziev I, Jones-Hall Y, Valentine JF, Webb CR, Furr KL, Grisham M (2015). Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases. Inflammatory bowel diseases, 21(7), 1652-73. (Read full publication)
    18. Wang MH, Okazaki T, Kugathasan S, Cho JH, Isaacs KL, Lewis JD, Smoot DT, Valentine JF, Kader HA, Ford JG, Harris ML, Oliva-Hemker M, Cuffari C, Torbenson MS, Duerr RH, Silverberg MS, Rioux JD, Taylor KD, Nguyen GC, Wu Y, Datta LW, Hooker S, Dassopoulos T, Kittles RA, Kao LW, Brant S (2012). Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflammatory bowel diseases, 18(12), 2277-87. (Read full publication)
    19. Johnson J, Affolter K, Boynton K, Chen X, Valentine J, Peterson (2018). CMV Disease in IBD: Comparison of Diagnostic Tests and Correlation with Disease Outcome. Inflammatory bowel diseases, 24(7), 1539-1546. (Read full publication)
    20. Ukhanova M, Culpepper T, Baer D, Gordon D, Kanahori S, Valentine J, Neu J, Sun Y, Wang X, Mai (2012). Gut microbiota correlates with energy gain from dietary fiber and appears to be associated with acute and chronic intestinal diseases. Clinical microbiology and infection, 18, 62-66.
    21. Valentine J (2001). Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo. American journal of physiology. Gastrointestinal and liver physiology, 281(4), G1044-50. (Read full publication)
    22. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu M (2013). Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clinical gastroenterology and hepatology, 11(3), 286-92; quiz e24. (Read full publication)
    23. Samadder NJ, Valentine JF, Guthery S, Singh H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith K (2019). Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clinical gastroenterology and hepatology, 17(9), 1807-1813.e1. (Read full publication)
    24. Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF, Porter N, Martens E, O'Connell R, Jacob V, Scherl E, Crawford C, Stephens WZ, Casjens SR, Longman RS, Round J (2019). Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Cell host & microbe, 25(2), 285-299.e8. (Read full publication)
    25. Runtsch MC, Hu R, Alexander M, Wallace J, Kagele D, Petersen C, Valentine JF, Welker NC, Bronner MP, Chen X, Smith DP, Ajami NJ, Petrosino JF, Round JL, O'Connell R (2015). MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis. Oncotarget, 6(30), 28556-72. (Read full publication)
    26. Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B, Siegel C, Valentine J, Smith M, Vande Casteele N, Dubinsky M, Cheifetz (2022). Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ open, 12(4), e057656. (Read full publication)
    27. Tse CS, Van Citters AD, Ricci B, Freundlich NZ, Lee M, Shah SA, Melmed GY, Siegel CA, van Deen WK, IBD Qorus (2022). Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. Journal of Crohn's & colitis, 16(3), 379-388. (Read full publication)
    28. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group (2022). Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. The lancet. Gastroenterology & hepatology, 7(2), 128-140. (Read full publication)
    29. Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG, LAUREL Study Group (2022). Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. The lancet. Gastroenterology & hepatology, 7(1), 28-37. (Read full publication)
    30. Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J, HIBISCUS Study Group (2022). Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The lancet. Gastroenterology & hepatology, 7(1), 17-27. (Read full publication)
    31. Tsai HY, Bronner MP, March JK, Valentine JF, Shroyer NF, Lai LA, Brentnall TA, Pan S, Chen (2022). Metabolic targeting of NRF2 potentiates the efficacy of the TRAP1 inhibitor G-TPP through reduction of ROS detoxification in colorectal cancer. Cancer letters, 549, 215915. (Read full publication)
    32. Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baía C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group (2022). Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. The lancet. Gastroenterology & hepatology, (Read full publication)
    33. Lebish EJ, Morgan NJ, Valentine JF, Beswick E (2022). MK2 Inhibitors as a Potential Crohn's Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity. Pharmaceuticals (Basel, Switzerland), 15(12), (Read full publication)
    34. Mohan BP, Fatima N, Khan SR, Kassab L, Chandan S, Asokkumar R, Valentine JF, Navaneethan U, Kochhar GS, Ma C, Jairath V, Singh (2023). Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. PMID: 37207296 DOI: 10.14309/ajg.0000000000002328. The American journal of gastroenterology, (Read full publication)
    35. Toy G, Colletier K, Hale G, Valentine J, Gawron AJ, Sossenheimer M, Peterson K, Aparicio R, Fang J (2023). Incidence of retained biopsy specimens after esophagogastroduodenoscopy and colonoscopy. Endoscopy international open, 11(7), E653-E659. (Read full publication)
    36. Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, Feagan BG, Neustifter B, Kadali H, Nazarey P, James A, Jairath V, Qasim Khan R (2023). Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). Clinical gastroenterology and hepatology, 22(7), 1487-1496.e12. (Read full publication)
    37. Chulkina M, Rohmer C, McAninch S, Panganiban RP, Villéger R, Portolese A, Ciocirlan J, Yang W, Cohen C, Koltun W, Valentine JF, Cong Y, Yochum G, Beswick EJ, Pinchuk I (2024). Increased activity of MAPKAPK2 within mesenchymal cells as a target for inflammation associated fibrosis in Crohn's Disease. Journal of Crohn's & colitis, 18(7), 1147-1161. (Read full publication)
    38. Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat M TNF promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF response. medRxiv (Preprint) 2024 Feb 6:2024. medRxiv,
    39. Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht A, Brensinger CM, Wu GD, Bittinger K, DINE-CD and SPARC IBD Investigators, Kaur M, Dassopoulos T, Snapper SB, Korzenik JR, Bohm M, Raffals L, Beniwal-Patel P, Hudesman D, Russ K, Brook L, Pekow J, Cross R, Wong U, Bishu S, Bewtra M, Lewis JD, Duerr R, Saha S, Caldera F, Scoville E, Deepak P, Ciorba (2024). Surgery for Crohn's Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts. Cellular and molecular gastroenterology and hepatology, 18(3), 101357. (Read full publication)
    40. Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, Feagan BG, Neustifter B, Kadali H, Nazarey P, James A, Jairath V, Qasim Khan R (2024). Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). Clinical gastroenterology and hepatology, 22(7), 1487-1496.e12. (Read full publication)
    41. Lee YJ, Li D, Mujukian A, Debbas P, Hampton M, Mengesha E, Cheng S, Ebinger JE, Chiorean M, Lum D, Damas OM, Braun J, McGovern DPB, Melmed GY, CORALE-IBD Study Grou (2024). Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease. Inflammatory bowel diseases, 30(8), 1430-1434. (Read full publication)
    42. Chulkina M, Rohmer C, McAninch S, Panganiban RP, Villéger R, Portolese A, Ciocirlan J, Yang W, Cohen C, Koltun W, Valentine JF, Cong Y, Yochum G, Beswick EJ, Pinchuk I (2024). Increased Activity of MAPKAPK2 within Mesenchymal Cells as a Target for Inflammation-Associated Fibrosis in Crohn's Disease. Journal of Crohn's & colitis, 18(7), 1147-1161. (Read full publication)
    43. Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat (2024). TNF promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF response. (Read full publication)
    44. Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht AL, Brensinger CM, Wu GD, Bittinger K, DINE-CD, SPARC IBD Investigator (2024). Surgery for Crohn's Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts. Cellular and molecular gastroenterology and hepatology, 18(3), 101357. (Read full publication)
    45. Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat (2024). TNF Promoter Hypomethylation Is Associated With Mucosal Inflammation in IBD and Anti-TNF Response. Gastro hep advances, 3(7), 888-898. (Read full publication)
    46. Danese S, Rothenberg ME, Lim JJ, Ding HT, McBride JM, Chen Y, Dash A, Mar JS, Keir M, Peyrin-Biroulet L, Panes J, Colombel JF, Feagan B, Valentine JF, Schreiber (2024). A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis. Clinical gastroenterology and hepatology, (Read full publication)
    47. Peterson LK, Nandakumar V, Valentine JF, Delgado JC, Saadalla A (2025). The Utility of the Immunoglobulin A Flag Used in Celiac Disease Serology Testing on a Particle-Based Multianalyte Technology Platform. Clinical chemistry, 71(7), 818-820. (Read full publication)
    48. Mellema RA, Queisser KA, Ajanel A, Albtoush N, Smith L, Rondina M, Will J, Valentine JF, Petrey A (2025). Layilin inhibits integrin activation, and its loss results in platelet hyperactivation via Rac1 in inflammatory bowel disease. Blood, (Read full publication)
    49. Tsai HY, Chen MH, Yun J, Lai LA, Valentine JF, Bronner MP, Brentnall TA, Pan S, Chen (2025). Restricting metabolic plasticity enhances stress adaptation through the modulation of PDH and HIF1A in TRAP1-depleted colon cancer. Cancer letters, 632, 217977. (Read full publication)

    Abstract

    1. Gaidos JKJ, Sultan S, Dahl W, Valentine J (2010). Vitamin D Deficiency in Inflammatory Bowel Disease. Advances in IBD Annual CCFA Meeting. Ft. Lauderdale, FL.
    2. Mach A, Glover S, Valentine J (2012). GM-CSF and IL23 Protect the Intestinal Epithelial Barrier from Disruption by IFN Treatment.

  • News & Podcasts

    Podcasts